Copyright © 2004 by the European Society of Cardiology.
Clinical research
Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study
a Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, 22–28 Princess Road West, Leicester LE1 6TP, UK
b Cardiology Group, Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Groby Road, Leicester, UK
c Department of Cardiology, The Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
d Roche Molecular Systems Inc, 1145 Atlantic Avenue, Alameda, CA 94501, USA
e Hoffmann-La Roche Ltd, Roche Genetics, Pharmaceuticals Division, CH-4070 Basel, Switzerland
Received July 11, 2003;
revised October 31, 2003;
accepted November 27, 2003
* Corresponding author. Tel.: +44-0-116-252-3156; fax: +44-0-116-252-3272
E-mail address: mt47{at}leicester.ac.uk
See page 451 for the editorial comment on this article1
Aim To identify polymorphisms and haplotypes in candidate genes that predispose to myocardial infarction (MI) using a multilocus approach.
Methods and results 1052 subjects, comprising 547 acute MI cases and 505 controls were studied. The association between MI and 58 SNPs in 35 candidate genes (generating 61 016 individual genotypes), and between MI and estimated haplotypes at 14 loci encompassing 16 genes was investigated. Two individual gene variants and haplotypes at two loci showed statistical association with MI. The 
-adducin 460trp variant (OR 0.73, 95% CI 0.59–0.91, 
) and the cholesteryl ester transfer protein –629A variant (OR 0.82, 95% CI 0.68–0.97, 
) were both associated with a significant protective effect on MI, as was the paraoxonase 1/paraoxonase 2 haplotype comprising met55 and gln192 in paraoxonase 1 and cys311 in paraoxonase 2 (OR 0.52, 95% CI 0.39–0.77, 
). The apolipoprotein C III haplotypes CCTTCG and ATCCCG at positions –641*–482*–455*1100*3175*3206 were associated with an increased risk of MI, odds ratios 1.41 (95% CI 1.06–1.76, 
) and 1.71 (95% CI 1.28–2.14, 
), respectively.
Conclusions We report associations of two polymorphisms and haplotypes at two loci with risk of MI that warrants testing in future studies. Furthermore, we demonstrate the application of a multilocus assay in the setting of a large association study and the additional benefit gained from the study of haplotypes to identify variants influencing risk of coronary heart disease.
Key Words: Genetics • Myocardial infarction • Risk factors
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Molecular genetics of myocardial infarction: many genes, more questions than answers
- Giuseppe Vassalli and Bernhard R Winkelmann
EHJ 2004 25: 451-453.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  T. Freilinger, S. Bevan, S. Ripke, A. Gschwendtner, P. Lichtner, B. Muller-Myhsok, H. -E. Wichmann, H. S. Markus, T. Meitinger, and M. Dichgans Genetic Variation in the Lymphotoxin-Alpha Pathway and the Risk of Ischemic Stroke in European Populations Stroke, March 1, 2009; 40(3): 970 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Sagoo, I. Tatt, G. Salanti, A. S. Butterworth, N. Sarwar, M. van Maarle, J. W. Jukema, B. Wiman, J. J. P. Kastelein, A. M. Bennet, et al. Seven Lipoprotein Lipase Gene Polymorphisms, Lipid Fractions, and Coronary Disease: A HuGE Association Review and Meta-Analysis Am. J. Epidemiol., December 1, 2008; 168(11): 1233 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Manunta, G. Lavery, C. Lanzani, P. S. Braund, M. Simonini, C. Bodycote, L. Zagato, S. Delli Carpini, C. Tantardini, E. Brioni, et al. Physiological Interaction Between {alpha}-Adducin and WNK1-NEDD4L Pathways on Sodium-Related Blood Pressure Regulation Hypertension, August 1, 2008; 52(2): 366 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk JAMA, June 18, 2008; 299(23): 2777 - 2788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koch, P. Hoppmann, J. Biele, J. C. Mueller, A. Schomig, and A. Kastrati Fibrinogen Genes and Myocardial Infarction: A Haplotype Analysis Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koch, P. Hoppmann, E. Michou, V. Jung, A. Pfeufer, J. C. Mueller, C. Gieger, H.-E. Wichmann, T. Meitinger, A. Schomig, et al. Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans Hum. Mol. Genet., August 1, 2007; 16(15): 1821 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Isaacs, Y. S. Aulchenko, A. Hofman, E. J. G. Sijbrands, F. A. Sayed-Tabatabaei, O. H. Klungel, A.-H. Maitland-van der Zee, B. H. Ch. Stricker, B. A. Oostra, J. C. M. Witteman, et al. Epistatic Effect of Cholesteryl Ester Transfer Protein and Hepatic Lipase on Serum High-Density Lipoprotein Cholesterol Levels J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2680 - 2687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Morgan, H. M. Krumholz, R. P. Lifton, and J. A. Spertus Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study JAMA, April 11, 2007; 297(14): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Casas, G. L. Cavalleri, L. E. Bautista, L. Smeeth, S. E. Humphries, and A. D. Hingorani Endothelial Nitric Oxide Synthase Gene Polymorphisms and Cardiovascular Disease: A HuGE Review Am. J. Epidemiol., November 15, 2006; 164(10): 921 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Keavney, J. Danesh, S. Parish, A. Palmer, S. Clark, L. Youngman, M. Delepine, M. Lathrop, R. Peto, R. Collins, et al. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization' Int. J. Epidemiol., August 1, 2006; 35(4): 935 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bianchi Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1536 - R1549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Ginsburg, M. P. Donahue, and L. K. Newby Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Smith, R. Harbord, J. Milton, S. Ebrahim, and J. A.C. Sterne Does Elevated Plasma Fibrinogen Increase the Risk of Coronary Heart Disease?: Evidence from a Meta-Analysis of Genetic Association Studies Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2228 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, L. Thijs, T. Kuznetsova, L. Zagato, H. Struijker-Boudier, G. Bianchi, and J. A. Staessen Cardiovascular Risk in Relation to {alpha}-Adducin Gly460Trp Polymorphism and Systolic Pressure: A Prospective Population Study Hypertension, September 1, 2005; 46(3): 527 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bianchi, P. Ferrari, and J. A. Staessen Adducin Polymorphism: Detection and Impact on Hypertension and Related Disorders Hypertension, March 1, 2005; 45(3): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Moreno and V. Fuster The year in atherothrombosis J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2099 - 2110. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vassalli and B. R Winkelmann Molecular genetics of myocardial infarction: many genes, more questions than answers Eur. Heart J., March 2, 2004; 25(6): 451 - 453. [Full Text] [PDF]
|
|